Virtual ACC 2020 | PRECOMBAT: 10 Years for Surgery vs. Angioplasty in Left Main Coronary Artery Disease

After 10 years of follow-up, there were no significant differences in the rates of major adverse cardiovascular or cerebrovascular events among patients with left main coronary artery disease randomized to angioplasty or surgery. Since this was the first study to randomize patients with left main coronary artery disease to angioplasty or surgery, it enrolled very few patients. As a consequence, it lacks the statistical power to generate definitive conclusions.

The PRECOMBAT (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study randomized 300 patients to angioplasty with a sirolimus-eluting stent and another 300 patients to surgery, to treat left main coronary artery disease in 13 Korean hospitals between 2004 and 2009.

The follow-up was extended to 10 years for all patients, with a mean of 11.3.

After this incredibly long period, the primary composite endpoint of death, infarction, stroke, or target vessel revascularization occurred in 29.8% of patients in the angioplasty arm and 24.7% of patients in the surgery arm (hazard ratio [HR]: 1.25; 95% confidence interval [CI]: 0.93-1.69).


Read also: Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM.


The outcomes are practically identical between strategies once revascularization is excluded (18.2% vs. 17.5%; HR: 1.00; 95% CI: 0.70 to 1.44).

All-cause death rates were also quite similar (14.5% vs. 13.8%).

The only variable differentiating both strategies at 10 years is, as expected, target vessel revascularization (16.1% vs. 8.0%).

Conclusion

The 10-year follow-up of pioneer study PRECOMBAT shows us similar rates of major adverse cardiovascular or cerebrovascular events among patients with left main coronary artery lesions randomized to angioplasty or surgery.

precombat-10-anos

Original Title: Ten-Year Outcomes After Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease. Extended Follow-Up of the PRECOMBAT Trial.

Reference: Duk-Woo Park et al. Circulation 2020; Epub ahead of print y presentado en forma virtual en el ACC 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....